Literature DB >> 10070896

Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer.

M M Borner1, P Brousset, B Pfanner-Meyer, M Bacchi, S Vonlanthen, M A Hotz, H J Altermatt, D Schlaifer, J C Reed, D C Betticher.   

Abstract

Proteins of the Bcl-2 family as well as p53 are important regulators of apoptosis. Alterations in the expression of these proteins can contribute to the formation of cancer, as well as influence tumour response to chemo- and radiotherapy. We used antibodies specific for the human Bcl-2, Mcl-1, Bax, Bak and p53 proteins to examine the expression of these apoptosis-regulating genes in 49 archival specimens of patients with radically resected non-small-cell lung cancer (NSCLC). Tumour cells containing immunostaining for the antiapoptotic proteins Bcl-2 and Mcl-1 were present in 31% and 58% of the cases evaluated, respectively, whereas immunopositivity for the proapoptotic proteins Bax and Bak was found in 47% and 58% of the samples. p53 immunopositivity was detected in 61% of the samples. The expression of Bcl-2 and p53 and the expression of Mcl-1 and Bax showed a positive association (P = 0.02 and P = 0.06 respectively), whereas the expression of Bax was inversely related to p53 (P = 0.008). The expression of Bcl-2 had a negative influence on relapse-free survival in this population of primary resected NSCLC patients (P = 0.02). The expression of p53 and Bcl-2 was significantly associated with metastasis-free survival (P < 0.01). Only patients with p53-positive tumours developed metastases during the follow-up period. Our results establish the frequent expression of the Bcl-2 family proteins Bcl-2, Mcl-1, Bax and Bak in NSCLC. It can be expected that Bcl-2 family members have no straightforward impact on clinical outcome in this disease because their interactions in the regulation of apoptosis are complex.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10070896      PMCID: PMC2362678          DOI: 10.1038/sj.bjc.6690152

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.

Authors:  R M Apolinario; P van der Valk; J S de Jong; W Deville; J van Ark-Otte; A M Dingemans; J C van Mourik; P E Postmus; H M Pinedo; G Giaccone
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

2.  Identification of a p53-dependent negative response element in the bcl-2 gene.

Authors:  T Miyashita; M Harigai; M Hanada; J C Reed
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

Review 3.  Clinical implications of the p53 tumor-suppressor gene.

Authors:  C C Harris; M Hollstein
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

Review 4.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

5.  bcl-2 protein in non-small-cell lung carcinoma.

Authors:  F Pezzella; H Turley; I Kuzu; M F Tungekar; M S Dunnill; C B Pierce; A Harris; K C Gatter; D Y Mason
Journal:  N Engl J Med       Date:  1993-09-02       Impact factor: 91.245

6.  Accumulation of p53 protein correlates with a poor prognosis in human lung cancer.

Authors:  D C Quinlan; A G Davidson; C L Summers; H E Warden; H M Doshi
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

7.  Immunohistochemical study of p53 in human lung carcinomas.

Authors:  E Brambilla; S Gazzeri; D Moro; C Caron de Fromentel; V Gouyer; M Jacrot; C Brambilla
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

8.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.

Authors:  I Chiba; T Takahashi; M M Nau; D D'Amico; D T Curiel; T Mitsudomi; D L Buchhagen; D Carbone; S Piantadosi; H Koga
Journal:  Oncogene       Date:  1990-10       Impact factor: 9.867

9.  The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.

Authors:  R Silvestrini; S Veneroni; M G Daidone; E Benini; P Boracchi; M Mezzetti; G Di Fronzo; F Rilke; U Veronesi
Journal:  J Natl Cancer Inst       Date:  1994-04-06       Impact factor: 13.506

10.  Similarity of apoptosis induction by 2-chlorodeoxyadenosine and cisplatin in human mononuclear blood cells.

Authors:  M M Borner; F Joncourt; M A Hotz
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  27 in total

1.  FBXO4 inhibits lung cancer cell survival by targeting Mcl-1 for degradation.

Authors:  C Feng; F Yang; J Wang
Journal:  Cancer Gene Ther       Date:  2017-08-04       Impact factor: 5.987

Review 2.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

3.  Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer.

Authors:  Thaddeus D Allen; Chang Qi Zhu; Kirk D Jones; Naoki Yanagawa; Ming-Sound Tsao; J Michael Bishop
Journal:  Cancer Res       Date:  2011-03-15       Impact factor: 12.701

4.  Deregulated BCL-2 family proteins impact on repair of DNA double-strand breaks and are targets to overcome radioresistance in lung cancer.

Authors:  Sarah A Wieczorek; Frank Breitenbuecher; Aashish Soni; Katja Paul-Konietzko; Sophie Ziegler; Ali Sak; George Iliakis; Martin Schuler
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-21       Impact factor: 4.553

5.  Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.

Authors:  Kwang Woon Kim; Luigi Moretti; Lauren Rhea Mitchell; Dae Kwang Jung; Bo Lu
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

6.  Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.

Authors:  Timothy G Whitsett; Ian T Mathews; Michael H Cardone; Ryan J Lena; William E Pierceall; Michael Bittner; Chao Sima; Janine LoBello; Glen J Weiss; Nhan L Tran
Journal:  Mol Cancer Res       Date:  2014-01-27       Impact factor: 5.852

7.  High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology.

Authors:  Valsamo K Anagnostou; Frank J Lowery; Vassiliki Zolota; Vassiliki Tzelepi; Arun Gopinath; Camil Liceaga; Nikolaos Panagopoulos; Konstantina Frangia; Lynn Tanoue; Daniel Boffa; Scott Gettinger; Frank Detterbeck; Robert J Homer; Dimitrios Dougenis; David L Rimm; Konstantinos N Syrigos
Journal:  BMC Cancer       Date:  2010-05-09       Impact factor: 4.430

8.  Roles of caveolin-1 on anoikis resistance in non small cell lung cancer.

Authors:  Preedakorn Chunhacha; Pithi Chanvorachote
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-09-20

9.  Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR.

Authors:  Zafer Cetin; Gulay Ozbilim; Abdullah Erdogan; Guven Luleci; Sibel Berker Karauzum
Journal:  Med Oncol       Date:  2009-09-10       Impact factor: 3.064

Review 10.  Molecular pathways and therapeutic targets in lung cancer.

Authors:  Emma Shtivelman; Thomas Hensing; George R Simon; Phillip A Dennis; Gregory A Otterson; Raphael Bueno; Ravi Salgia
Journal:  Oncotarget       Date:  2014-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.